Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platform
Oxford, UK – 9th February 2022 – Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, announces the completion of a further $4.3m (£3.2m) to close its $12.5m (£9.2m) Series A financing round. The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.
